ORKA Insider Trading

Oruka Therapeutics, Inc. (ORKA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $7.15B, listed on NASDAQ, employing roughly 68 people, carrying a beta of -0.39 to the broader market. Oruka Therapeutics, Inc. Led by Lawrence Otto Klein, public since 1997-08-08.

In the last 12 months, Oruka Therapeutics, Inc. insiders made 0 buy transactions and 139 sale transactions.

DateNameTypeSharesPriceValue
Nov 13, 2026Agarwal ArjunM-Exempt8,542$12.50$106.8K
Nov 13, 2026Agarwal ArjunM-Exempt1,458$34.39$50.1K
Nov 13, 2026Agarwal ArjunM-Exempt1,458$34.39$50.1K
Nov 13, 2026Agarwal ArjunS-Sale500$101.98$51.0K
Nov 13, 2026Agarwal ArjunS-Sale801$103.16$82.6K
Nov 13, 2026Agarwal ArjunM-Exempt8,542$12.50$106.8K
Nov 13, 2026Agarwal ArjunS-Sale799$104.25$83.3K
Nov 13, 2026Agarwal ArjunS-Sale6,842$105.28$720.3K
Nov 13, 2026Agarwal ArjunS-Sale958$106.18$101.7K
Nov 13, 2026Agarwal ArjunS-Sale100$107.00$10.7K

ORKA Insider Activity by Quarter

Reported Form 4 and Form 5 lines under ORKA's own SEC company ID, by transaction date, back to Q4 2024. Purchases and sales are code P / S (open market or private) in the company's shares; other lines are purchases and sales of other securities (options, warrants, preferred), awards, exercises, tax withholding, gifts and other acquisitions and dispositions. Later filings and amendments can change the current quarter. Earlier quarters are not shown: the filings read reach back to Sep 13, 2024, and a quarter counts only when every filing for it was read.

QuarterPurchasesBoughtSalesSoldOther Lines
Q4 2026 (so far)0N/A34$9.5M20
Q3 20260N/A50$319.8M40
Q2 20260N/A34$12.0M28
Q1 20260N/A17$1.4M27
Q4 20250N/A4$214.3K5
Q3 20250N/A0N/A2
Q2 20250N/A0N/A5
Q1 20255$1.4M0N/A4
Q4 20240N/A0N/A2

ORKA Institutional Ownership (13F)

As of Jun 30, 2026 (Q2 2026), 256 institutions reported holding 74,134,303 ORKA shares, valued at $7.05B as reported, 141.0% of its market cap (market cap of Jun 26, 2026). That is +72 institutions from the quarter before. Among managers whose reports for both quarters are comparable, 96 opened a position, 26 closed one, 94 added and 47 trimmed.

Top Holders, Q2 2026

ManagerSharesValueChange
FMR LLC9,057,645$862.0M+1,626,242
BlackRock, Inc.4,990,181$474.9M+1,463,094
Venrock Adviser, LLC4,148,428$394.8MUnchanged
Fairmount Funds Management LLC3,705,262$352.6MUnchanged
Capital World Investors3,401,639$323.7MNew
RTW INVESTMENTS, LP3,139,030$298.7M+1,080,882
STATE STREET CORP2,673,090$254.4M+1,059,629
VANGUARD CAPITAL MANAGEMENT LLC2,360,971$224.7M+501,340
Paradigm Biocapital Advisors LP2,144,526$204.1M-175,790
Deep Track Capital, LP1,926,000$183.3M-108,203

By Quarter

QuarterInstitutionsSharesValue
Q2 202625674,134,303$7.05B
Q1 202618452,897,134$2.61B
Q4 202514352,851,763$1.60B
Q3 202510545,571,928$876.1M
Q2 20258134,431,549$386.0M
Q1 20257131,776,545$326.1M
Q4 20246631,038,321$606.6M
Q3 20244124,559,501$604.2M

From the SEC's Form 13F data sets: investment managers with $100 million or more in Section 13(f) securities report their holdings each quarter, up to 45 days after it ends; a restated filing replaces the original, and values are as the managers reported them (a position whose price runs about 1,000 times below other managers', from a manager whose positions mostly do, is read as reported in thousands of dollars). The same shares can be reported by more than one manager, so totals can count some twice.

ETFs Holding ORKA

FundWeight of ORKAShares (as reported)Value (as reported)Source updated
XBI State Street SPDR S&P Biotech ETF1.70%1,705,331$182.8MNov 12, 2026
IWM iShares Russell 2000 ETF0.18%1,305,011$139.9MNov 12, 2026
IWO iShares Russell 2000 Growth ETF0.36%475,572$51.0MNov 12, 2026
IBB iShares Biotechnology ETF0.43%452,494$48.5MNov 12, 2026
SCHA Schwab U.S. Small-Cap ETF0.14%304,177$32.0MNov 13, 2026
CGMM Capital Group U.S. Small and Mid Cap ETF0.54%188,832$20.2MNov 13, 2026
TCAF T. Rowe Capital Appreciation Equity ETF0.23%180,724$19.4MNov 13, 2026
SBIO ALPS Medical Breakthroughs ETF4.54%80,990$8.5MNov 13, 2026
FESM Fidelity Enhanced Small Cap ETF0.12%76,325$8.2MNov 13, 2026
ITOT iShares Core S&P Total U.S. Stock Market ETF0.01%75,183$8.1MNov 12, 2026
LABU Direxion Daily S&P Biotech Bull 3X Shares0.33%61,663$6.6MNov 13, 2026
DFAS Dimensional - US Small Cap ETF0.02%60,499$6.5MNov 13, 2026
FTXH First Trust Nasdaq Pharmaceuticals ETF0.53%60,499$6.5MNov 12, 2026
DWAS Invesco Dorsey Wright SmallCap Momentum ETF1.62%60,047$6.4MNov 12, 2026
FSMD Fidelity Small-Mid Multifactor ETF0.17%38,543$4.1MNov 13, 2026

From each fund's latest holdings file on record that shows ORKA's listed security itself. A file counts when its line count is consistent with the fund's reported holdings count (at most twice it plus 10, or at most 1,000 lines for a reported count of exactly 10, which the data source gives many funds as a cap), read with that file or inherited from the fund's last classified file (within 20% of its line count, read within 60 days). Funds whose line for the company could not be confirmed as ORKA's listed security, or that hold it through underlying funds (look-through), are not listed. Only long positions count: a fund is left out when any of its lines for ORKA reports a negative weight, share count or value, or none of them above zero (a short position, or figures that disagree). Shares, value and weight are as reported in each fund's file, dated by the data source's last update of that file (not the date of the positions); the weight is ORKA's share of that fund.

How to Read ORKA Insider Activity

Net insider sentiment skews to the sell side over the trailing twelve months: 139 sales versus 0 buys. Insider sales carry less informational weight than buys because they are often driven by liquidity, tax planning, or pre-scheduled Rule 10b5-1 trading plans rather than negative information. The transaction type alone does not say whether a sale was made on the open market or privately, or under a 10b5-1 plan; the filing's plan checkbox and footnotes do. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.

Learn how insider trading is reported and how to read the data →

Frequently asked ORKA insider trading questions

How active are ORKA insiders right now?
Over the trailing twelve months, Oruka Therapeutics, Inc. (ORKA) insiders made 0 buy transactions and 139 sale transactions. Net insider sentiment over the trailing twelve months tilts to the sell side (139 sales vs 0 buys). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
What counts as an insider transaction?
Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
Are ORKA insider buys a bullish signal?
Insider purchases (Type P, made on the open market or privately; the code covers both) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
How do ORKA insider transactions affect options pricing?
Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.